Literature DB >> 9553954

Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects.

A K Halladay1, H Fisher, G C Wagner.   

Abstract

Previous studies have reported the use of combined serotonergic and dopaminergic agonists in the treatment of obesity and alcoholism. Along these lines, phentermine plus fenfluramine has been suggested as a possible clinical treatment for alcohol craving. To determine the neurochemical effects of a combined treatment of phentermine plus fenfluramine, animals were injected subcutaneously with saline, phentermine 12 mg/kg, fenfluramine 16 mg/kg, or a combination of phentermine plus fenfluramine. One hour after injection, animals were sacrificed and neurochemical analysis performed. Furthermore, separate groups of animals were given the same injections 8 times, 12 hours apart, to determine the effects on body weight and to detect a possible exacerbation of fenfluramine induced toxicity. The drug combination produced a significant rise in dopamine in the striatum, greater than that seen with either drug alone. Furthermore, the addition of phentermine reduced the fenfluramine induced rise in striatal 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindolacetic acid (5-HIAA). Phentermine plus fenfluramine combination produced a greater weight loss than either drug alone, however, it did not produce a significantly greater drop in striatal serotonin or 5-HIAA levels above that induced by fenfluramine alone. Thus, while previous studies report the potentiated neurotoxicity of phentermine plus fenfluramine over fenfluramine alone, the present study does not indicate that such an effect occurs following an administration regimen analogous to that of patients treated with the drug combination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553954

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  2 in total

1.  Specification of distinct dopaminergic neural pathways: roles of the Eph family receptor EphB1 and ligand ephrin-B2.

Authors:  Y Yue; D A Widmer; A K Halladay; D P Cerretti; G C Wagner; J L Dreyer; R Zhou
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

2.  Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat.

Authors:  Andrew J Grottick; Kevin Whelan; Erin K Sanabria; Dominic P Behan; Michael Morgan; Carleton Sage
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.